The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Addyi
Synonyms :
flibanserin
Class :
Serotonin 5-HT Receptor Agonists
Brand Name :
Addyi
Synonyms :
flibanserin
Class :
Serotonin 5-HT Receptor Agonists
Dosage Forms & StrengthsÂ
TabletÂ
100mgÂ
100mg orally once at bedtime
If there is no progress after eight weeks, treatment is stopped
Not indicatedÂ
Refer adult dosingÂ
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of flibanserin
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
May increase the hypoglycemic effect of each other when combined
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
ciprofloxacin increases the level of flibanserin by affecting the CYP3A4 metabolism of hepatic/intestinal enzymes. Coadministration with strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope may occur .
when both drugs are combined, there may be an increased effect of cobimetinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
lapatinib increases the effect of flibanserin by altering the intestinal or hepatic CYP3A4 enzyme metabolism
When both drugs are combined, there may be an increased effect of flibanserin by affecting hepatic or intestinal enzyme CYP3A4 metabolism 
when both drugs are combined, there may be an increase in the effect of flibanserin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
the serum concentration of digitoxin is increased by flibanserin. Assessment of serum concentrations of digitoxin is recommended before therapy
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
by affecting intestinal metabolism, the effect of flibanserin may be increased
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may enhance the serum concentrations of flibanserin
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
may increase the CNS depressant effect of flibanserin
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
the level of lenvatinib increases due to a decrease in metabolism by eluxadoline
the effect of flibanserin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of flibanserin 
CYP3A4 inducers decrease the concentration of flibanserin in serum
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
it increases the toxicity of SSRIs
it increases the toxicity of SSRIs
it increases the effect of SSRIs
it increases the effect of SSRIs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may have an increased serotonergic effect when combined with selective serotonin reuptake inhibitors
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the serum concentration of flibanserin
may enhance the serum concentration of flibanserin
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may enhance the serum concentrations of P-glycoprotein-ABCB1 inhibitors
may increase the CNS depressant effect of CNS depressants
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the concentration of serum when combined with flibanserin
flibanserin: they may enhance the serum concentration of hormonal contraceptives
flibanserin: they may enhance the serum concentration of hormonal contraceptives
flibanserin: they may enhance the serum concentration of hormonal contraceptives
flibanserin: they may enhance the serum concentration of hormonal contraceptives
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The potential for increased CNS depression risk or seriousness occurs when flibanserin is used together with pinazepam
The potential for increased CNS depression risk or seriousness occurs when flibanserin is used together with pipecuronium
When flibanserin is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when flibanserin is used together with fencamfamin
When flibanserin is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When flibanserin is used together with piroxicam, this leads to increased risk or seriousness of hypertension
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
may decrease the therapeutic effect when combined with Alpha2-Agonists
when both drugs are combined, there may be an increased level of serum concentration of etoposide   
when both drugs are combined, there may be a decreased metabolism of vincristine  
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration  
CYP3A4 inhibitors increase the concentration of flibanserin in serum
hormonal contraceptives increase the toxicity of flibanserin in serum
it may increase the effect of other selective serotonin reuptake inhibitors
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
may increase the antiplatelet effect
may increase the hyponatremic effect of thiazide and thiazide-like diuretics
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the toxic effect of antipsychotic agents
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
empagliflozin and linagliptinÂ
may increase the hypoglycaemic effect when combined
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
SSRIs increase the CNS depressing effect of brexanolone
Actions and Spectrum:Â
Frequency definedÂ
>10%Â
Dizziness (11.4%)Â
Nausea (10.4%)Â
Somnolence (11.2%)Â
1-10%Â
Fatigue (9.2%)Â
Dry mouth (2.4%)Â
Constipation (1.6%)Â
Sedation (1.3%)Â
Vertigo (1%)Â
Insomnia (4.9%)Â
Anxiety (1.8%)Â
Abdominal pain (1.5%)Â
Rash (1.3%)Â
Metrorrhagia (1.4%)Â
Post-marketing reportsÂ
AnaphylaxisÂ
Black box warning:Â
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
flibanserin is rapidly absorbed after oral administration, with a bioavailability of 33%. Peak plasma concentrations are reached within 0.75 hours.Â
DistributionÂ
flibanserin is highly protein-bound (98%), primarily to albumin. Its volume of distribution is estimated to be approximately 1000 LÂ
MetabolismÂ
flibanserin is primarily metabolized in the liver by the cytochrome P450 (CYP) enzyme system, with CYP3A4 being the major enzyme. CYP2C19 also metabolizes it to a lesser extent. The major metabolite, which oxidative N-dealkylation forms, has negligible pharmacological activity.Â
Elimination and ExcretionÂ
flibanserin and its metabolites are eliminated primarily via feces (51%) and, to a lesser extent, urine (44%). The elimination half-life is approximately 11 hours.Â
Administration:Â
Patient information leafletÂ
Generic Name: flibanserinÂ
Pronounced: [ flib-AN-ser-in ]Â
Why do we use flibanserin?Â
flibanserin is primarily used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is a condition characterized by a persistent lack of sexual desire or interest, which causes significant distress or interpersonal difficultyÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
